drugset / Trial / NCT02683577

Study to Evaluate a Dose of Telotristat Etiprate in Male and Female With Mild, Moderate and Severe Hepatic Insufficiency and Matched Healthy Subjects

NCT02683577

Phase 1 Completed 24 enrolled Ipsen
NaSingle-groupOpen-labelBasic science

Summary

The purpose of the protocol is to assess the pharmacokinetics, safety and tolerability of a single dose of telotristat etiprate in subjects with various stages of hepatic impairment compared to healthy control subjects.

Timeline

Start
2016-02
Primary completion
2016-07
Completion
2016-07

Drugs

EvaluationDrugModalityDoseRoute
Subject Telotristat etiprate Unknown 500 mg Oral

Indications

No indication recorded.